Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.16/817
Título: Practical aspects of the use of target controlled infusion with remifentanil in neurosurgical patients: predicted cerebral concentrations at intubation, incision and extubation
Autor: Ferreira, D.
Nunes, C.
Antunes, L.
Lobo, F.
Amorim, P.
Palavras-chave: Remifentanil
Data: 2006
Editora: Société belge d'anesthésie et de réanimation
Citação: Acta Anaesthesiol Belg. 2006;57(3):265-70.
Resumo: Abstract Remifentanil has important side effects and it is not easy to know what remifentanil concentrations should be used during different endpoints of anaesthesia. We analyzed the remifentanil predicted effect-site concentrations (RemiCe) at different events during neurosurgical procedures and assessed if the concentrations used were clinically adequate. BIS and haemodynamic parameters were collected every 5 seconds. Predicted cerebral concentration of propofol (PropCe) and RemiCe were analyzed immediately prior to respective stimulus, and 30, 60 and 90 seconds after. RemiCe were 2.2 +/- 0.3, 6 +/- 2.6 and 2.2 +/- 0.9 ng ml(-1) at intubation, incision and extubation, respectively. PropCe observed in the same periods were 5 +/- 1, 2.6 +/- 0.9 and 1 +/- 0.3 microg ml(-1), also respectively. The remifentanil concentrations used in our patients were lower than reported concentrations, while being clinically adequate to minimize the haemodynamic response to stimulation.
Peer review: yes
URI: http://hdl.handle.net/10400.16/817
ISSN: 0001-5164
Versão do Editor: http://www.sarb.be/fr/journal/artikels_acta_2006/artikels_acta_57_3/06-Ferreira.pdf
Aparece nas colecções:SA - Artigos publicados em revistas indexadas na Medline

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Practical aspects of the use of target controlled infusion.pdf127,49 kBAdobe PDFVer/Abrir

FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.